SURPASS-CVOT compared once-weekly tirzepatide with dulaglutide in adults with type 2 diabetes and high cardiovascular risk, showing a 9% relative risk reduction in MACE (HR 0.92, 95% CI 0.83 to 1.01)
Similarly to dulaglutide and s.c
Available from: Novo Nordisk: Company announcements
Semaglutide shows promise in reducing cravings for alcohol, heavy drinking The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new research led by Christian Hendershot, PhD, first author of the study, professor of Population and Public Health Sciences and director of Clinical Research at USC Institute for Addiction Science, and Klara Klein, MD, PhD, senior author, assistant professor at the Department of Medicines Division of Endocrinology and Metabolism at the UNC School of Medicine
agitation can expose it to oxygen and accelerate oxidation
There are no published interaction studies between semaglutide and NSAIDs